|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
Advanced Medical Isotopes Corporation Signs 1-Year Option to License Injectable Radiogel for High-dose Interstitial Radiation Therapy Developed at Pacific Northwest National Laboratory
2/28/2011 9:49:19 AM
KENNEWICK, Wash., Feb. 28, 2011 (GLOBE NEWSWIRE) -- James Katzaroff, Chairman and Chief Executive Officer of Advanced Medical Isotope Corporation (OTCBB:ADMD), a company engaged in the production and distribution of medical isotopes, has signed an option agreement with Battelle Memorial Institute, operator of Pacific Northwest National Laboratory (PNNL) for rights to an injectable "Radiogel" for High-dose Interstitial Radiation Therapy. Upon exercise of the option and execution of an exclusive license with Battelle, AMIC will have the exclusive right to further develop the technology, which is a microsphere-embedded, injectable polymer solution designed to maximize the radiation dose to cancerous tumors that cannot be removed surgically.
|
|
|
|
|
|
|
|
|
|
|